Baxter to establish new biopharma R&D center

Skip to Navigation

Blog Post

  • Published: Oct 3, 2014
  • Author: Jon Evans
  • Channels: Electrophoresis / Sample Preparation / HPLC / Laboratory Informatics / Proteomics & Genomics / Ion Chromatography / Detectors / Gas Chromatography / Atomic / MRI Spectroscopy / X-ray Spectrometry / Chemometrics & Informatics / Raman / UV/Vis Spectroscopy / Proteomics / Infrared Spectroscopy / Base Peak / NMR Knowledge Base

View comments on this post

The US pharmaceutical company Baxter International is to establish a new global innovation and R&D center for biopharmacetucals in Cambridge, Massachusetts, US. This follows Baxter's decision to hive off its biopharmaceutical business as an independent company called Baxalta in mid-2015.

The new R&D center will house 400 R&D staff, who will relocate from current sites in California and Europe, although Baxalta will retain certain R&D operations at its site in Vienna, Austria. In addition, the new center will house Baxalta's business development, oncology and biosimilars teams. The first phase of the 200,000-square feet center should open later this year, with subsequent phases following over the next two years.

'Our new innovation center will increase R&D collaboration and efficiency, connect us directly to a rich pool of talent in new and emerging biotech areas, and strengthen our ability to drive programs forward in cooperation with current and future partners,' said John Orloff, vice president and global head of research and development for Baxter BioScience.


There are currently no comments on this post.

Comment Form

You have to log in to comment on this post.

Log in using the form at the top of the page or register here.

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Most Viewed

Copyright Information

Interested in separation science? Visit our sister site

Copyright © 2019 John Wiley & Sons, Inc. All Rights Reserved